Skip to main content

Table 3 Univariate analysis (log-rank test) for overall survival (n = 24)

From: Survival and prognostic factors in patients undergoing pulmonary metastasectomy for lung metastases from retroperitoneal sarcoma

Variables n 3-year OS 95% CI P value
Age (years)     < 0.001
 < 56 11 90.9% 50.8–98.7  
 ≥ 56 13 38.5% 14.1–62.8  
Sex     0.28
 Male 4 50.0% 5.8–84.5  
 Female 20 65.0% 40.3–81.5  
Histological subtypes     0.01
 Leiomyosarcoma 19 73.7% 47.9–88.1  
 Dedifferentiated liposarcoma 3 NA NA  
 Others 2 NA NA  
Disease-free interval (months)     0.04
 < 15 months 9 44.4% 13.6–71.9  
 ≥ 15 months 15 73.3% 43.6–89.1  
Extent of lung metastases     0.2
 Unilateral 8 62.5% 22.9–86.1  
 Bilateral 16 62.5% 34.9–81.1  
Preoperative chemotherapy for lung metastases     0.84
 Yes 9 55.6% 20.4–80.5  
 No 15 66.7% 37.5–84.6  
NLR before the first PM     0.8
 < 1.92 6 83.3% 27.3–97.5  
 ≥ 1.92 18 55.6% 30.5–74.8  
NLR before the most recent PM     0.41
 < 2.48 15 60.0% 31.8–79.7  
 ≥ 2.48 9 66.7% 28.2–87.8  
Surgical approach     0.16
 Open 7 42.9% 9.8–73.4  
 Mini-thoracotomy 13 69.2% 37.3–87.2  
 VATS 4 75.0% 12.8–96.1  
Type of resection     0.31
 Lobectomy 1 100.0% NA  
 Segmentectomy 6 50.0% 11.1–80.4  
 Wedge resection 17 64.7% 37.7–82.3  
Size of the largest resected tumor     0.04
 < 27mm 17 76.5% 48.8–90.4  
 ≥ 27mm 7 28.6% 4.1–61.2  
Total number of resected tumors     0.6
 < 7 13 61.5% 30.8–81.8  
 ≥ 7 11 63.6% 29.7–84.5  
Complete resection     0.17
 Yes 20 70.0% 45.1–85.3  
 No 4 25.0% 0.9–66.5  
Repeated resection     0.41
 Yes 15 66.7% 37.5–84.6  
 No 9 55.6% 20.4–80.5  
  1. RPS Retroperitoneal sarcoma, NLR Neutrophil-to-lymphocyte ratio, PM Pulmonary metastasectomy